Abstract
Primary cardiac lymphomas (PCLs) are a rare clinical entity, in which treatment guidelines remain to be established. Rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) has been proposed, given that it involves a continuous infusion of anthracycline, reducing the risk of a cardiotoxicity and therefore the theoretical risk of perforation. However, the literature on this method of treatment is scarce. Herein, we present a unique case of a 75-year-old male, diagnosed with primary cardiac diffuse large B-cell lymphoma (DLBCL) with relatively unusual involvement of the coronary sinus, treated first with one cycle of R-EPOCH, followed by three cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to reduce said risk. To our knowledge, this is one of two cases, in which a patient with PCL was treated this way.
Original language | English (US) |
---|---|
Pages (from-to) | 2557-2560 |
Number of pages | 4 |
Journal | Annals of Hematology |
Volume | 103 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2024 |
Keywords
- Cardiotoxicity
- DLBCL
- Myocardial rupture
- PCL
- R-EPOCH
- Prednisone/therapeutic use
- Coronary Sinus/diagnostic imaging
- Humans
- Male
- Rituximab/administration & dosage
- Heart Neoplasms/drug therapy
- Vincristine/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Etoposide/administration & dosage
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Cyclophosphamide/administration & dosage
- Aged
- Doxorubicin/therapeutic use
ASJC Scopus subject areas
- Hematology